Results 11 to 20 of about 15,767 (251)

Expression of poly(Adenosine Diphosphate-Ribose) polymerase protein in breast cancer [PDF]

Journal of Mid-Life Health, 2022
Background: The use of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors for breast cancer (BC) therapy is the subject of debate, and there is an urgent need to understand much the expression and prognostic role of the PARP1 protein.
Akanksha, Shashi Prakash Mishra, Amrita Ghosh Kar, J S Karthik, Aviral Srivastava, Rahul Khanna, Ram Niwas Meena   +6 more
doaj   +4 more sources

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy [PDF]

Biomolecules, 2012
Treatments with Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have offered patients carrying cancers with mutated BRCA1 or BRCA2 genes a new and in many cases effective option for disease control.
Thomas Helleday, Cecilia E. Ström
doaj   +4 more sources

Model for Predicting Serious Hematological Adverse Events in Individuals With Ovarian Cancer Receiving Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Treatment: Prospective Cohort Study

JMIR Medical Informatics
BackgroundPredicting serious hematological adverse events (SHAEs) from poly (adenosine diphosphate ribose) polymerase inhibitors (PARPis) would allow us to prioritize patients with ovarian cancer at higher risk for more intensive ...
Xiaotong Lian, Yu Lei
doaj   +3 more sources

Natural occurence of a biopolymer, poly (adenosine diphosphate ribose)

Nucleic Acids Research, 1977
Evidence for the natural occurrence of poly(adenosine diphosphate ribose) in vivo was obtained using a sensitive radioimmunoassay and poly(adenosine diphosphate ribose) glycohydrolase, which specifically hydrolyzes poly(adenosine diphosphate ribose).
H, Sakura, M, Miwa, M, Tanaka, Y, Kanai, T, Shimada, T, Matsushima, T, Sugimura   +6 more
exaly   +7 more sources

Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. [PDF]

Cancer, 2020
Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC.   +17 more
europepmc   +5 more sources

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer. [PDF]

Cureus, 2022
Pancreatic cancer is the third most common cause of cancer death in the United States and eleventh worldwide. The majority of patients present with advanced disease with five-year overall survival of less than 10%. Traditional chemotherapy has been the mainstay treatment for years, with limited improvement in survival.
Sunkara T, Bandaru SS, Boyilla R, Kunadharaju R, Kukkadapu P, Chennamadhavuni A.   +5 more
europepmc   +4 more sources

Poly–adenosine diphosphate–ribose polymerase inhibition for myocardial protection: Pathophysiologic and physiologic considerations [PDF]

, 2004
Plantilles de l’Institut Barcelona Esports, de l’Institut Municipal del Paisatge Urbà i la Qualitat de Vida, de l’Institut Municipal d'Informàtica, de l’Institut Municipal d'Hisenda, de l’Institut Municipal d'Educació, de l’Institut Municipal de Mercats,
Wilhelm Bloch, Uwe Mehlhorn, Szabo, Burkle, Fischer, Schmitt, Shall, Nagayama   +7 more
core   +3 more sources

Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors [PDF]

Reviews in Cardiovascular Medicine
The Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including ...
Jie Ma, Caie Li, Wenjuan Wang, Xin Fan, Taotao Wei, Xin Ma, Yingdong Wang, Chuyan Feng, Jing Yu   +8 more
doaj   +2 more sources

Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis. [PDF]

PLoS ONE, 2017
BACKGROUND:Previous studies have shown that the poly (adenosine diphosphate-ribose) polymerase (PARP) level is a promising indicator of breast cancer. However, its prognostic value remains controversial. The present meta-analysis evaluated the prognostic
Weiqiang Qiao, Linlin Pan, Changgui Kou, Ke Li, Ming Yang   +4 more
doaj   +2 more sources

Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. [PDF]

Hematol Oncol Clin North Am, 2012
Recently, the development of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as a synthetic lethality approach has brought a major breakthrough in the treatment of breast cancer susceptibility gene (BRCA)-mutant cancers. Because sporadic cancers have also been found to commonly have other defects in DNA repair, PARP inhibitors are under
Park SR, Chen A.
europepmc   +4 more sources